Evan Seigerman on Tariffs' Impact on Pharmaceutical Stocks and Gilead's Outlook

Impact of Tariffs on Pharma

• ⚠️ Pharmaceutical tariffs are a source of uncertainty, with companies awaiting clarity on potential major levies.
• 💡 Many major biopharma companies like Eli Lilly manufacture supply within the United States, allowing them to better withstand tariff impacts.
• 📌 Companies with supply chains in Ireland often domicile their IP there for tax benefits but still manufacture and import products to the US.
• 💰 Generic makers are considered at higher risk due to already thin margins, potentially making production unprofitable if tariffs are imposed.
• 🌍 A significant portion of generic products and APIs are manufactured in India and China, making supply chain interruption a concern.

Gilead's Investment Potential

• 🚀 Gilead Sciences is presented as a potential buy, with enthusiasm for their long-acting PrEP launch, specifically the drug lenacapavir.
• 📈 The company's durable HIV business is highlighted as a strength, with a history of reinventing treatments to maintain profitability.
• 🔬 Gilead's cell therapy business is noted as being exempt from tariffs due to the personalized nature of these medications.